Therapeutic potential of interleukin-27 against cancers in preclinical mouse models

Izuru Mizoguchi; Yukino Chiba; Jun-Ichi Furusawa; Mingli Xu; Ren Tsunoda; Kaname Higuchi; Takayuki Yoshimoto

doi:10.1080/2162402X.2015.1042200

Therapeutic potential of interleukin-27 against cancers in preclinical mouse models

Oncoimmunology. 2015 May 27;4(10):e1042200. doi: 10.1080/2162402X.2015.1042200. eCollection 2015 Oct.

Authors

Izuru Mizoguchi¹, Yukino Chiba¹, Jun-Ichi Furusawa¹, Mingli Xu¹, Ren Tsunoda¹, Kaname Higuchi¹, Takayuki Yoshimoto¹

Affiliation

¹ Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.

Abstract

Since we first reported the antitumor efficacy of IL-27 in 2004, accumulating evidence obtained by several groups using a variety of preclinical mouse models indicates that IL-27 possesses potent antitumor activity against various types of tumors through multiple mechanisms depending on the characteristics of individual tumors without apparent adverse effects.

Keywords: IL-27; TLR3; TRAIL; antitumor; poly(I:C).